Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

4-28-2014

The Microbiome in Pediatric Cystic Fibrosis Patients: The Role of
Shared Environment Suggests a Window of Intervention
Thomas H. Hampton
Dartmouth College

Deanna M. Green
Duke University

Garry R. Cutting
Johns Hopkins University

Hilary G. Morrison
Marine Biological Laboratory

Mitchell L. Sogin
Marine Biological Laboratory

See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Genetics Commons, and the Medical Microbiology Commons

Dartmouth Digital Commons Citation
Hampton, Thomas H.; Green, Deanna M.; Cutting, Garry R.; Morrison, Hilary G.; Sogin, Mitchell L.; Gifford,
Alex H.; Stanton, Bruce A.; and O’Toole, George A., "The Microbiome in Pediatric Cystic Fibrosis Patients:
The Role of Shared Environment Suggests a Window of Intervention" (2014). Dartmouth Scholarship.
1302.
https://digitalcommons.dartmouth.edu/facoa/1302

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors
Thomas H. Hampton, Deanna M. Green, Garry R. Cutting, Hilary G. Morrison, Mitchell L. Sogin, Alex H.
Gifford, Bruce A. Stanton, and George A. O’Toole

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/1302

Hampton et al. Microbiome 2014, 2:14
http://www.microbiomejournal.com/content/2/1/14

SHORT REPORT

Open Access

The microbiome in pediatric cystic fibrosis
patients: the role of shared environment suggests
a window of intervention
Thomas H Hampton1, Deanna M Green2, Garry R Cutting3, Hilary G Morrison4, Mitchell L Sogin4, Alex H Gifford1,
Bruce A Stanton1 and George A O’Toole5*

Abstract
Background: Cystic fibrosis (CF) is caused by mutations in the CFTR gene that predispose the airway to infection.
Chronic infection by pathogens such as Pseudomonas aeruginosa leads to inflammation that gradually degrades
lung function, resulting in morbidity and early mortality. In a previous study of CF monozygotic twins, we
demonstrate that genetic modifiers significantly affect the establishment of persistent P. aeruginosa colonization in
CF. Recognizing that bacteria other than P. aeruginosa contribute to the CF microbiome and associated pathology,
we used deep sequencing of sputum from pediatric monozygotic twins and nontwin siblings with CF to
characterize pediatric bacterial communities and the role that genetics plays in their evolution.
Findings: We found that the microbial communities in sputum from pediatric patients living together were much
more alike than those from pediatric individuals living apart, regardless of whether samples were taken from
monozygous twins or from nontwin CF siblings living together, which we used as a proxy for dizygous twins. In
contrast, adult communities were comparatively monolithic and much less diverse than the microbiome of
pediatric patients.
Conclusion: Taken together, these data and other recent studies suggest that as patients age, the CF microbiome
becomes less diverse, more refractory to treatment and dominated by mucoid P. aeruginosa, as well as being
associated with accelerated pulmonary decline. Our studies show that the microbiome of pediatric patients is
susceptible to environmental influences, suggesting that interventions to preserve the community structure found
in young CF patients might be possible, perhaps slowing disease progression.
Keywords: Cystic fibrosis, Microbiome, Pseudomonas aeruginosa, Sputum

Findings
Background

Cystic fibrosis (CF) is an inherited disease that affects over
70,000 people worldwide. It is caused by mutations in the
CF transmembrane conductance regulator (CFTR) gene.
Mutations in CFTR reduce airway surface liquid volume,
thereby reducing mucociliary clearance of bacterial pathogens that cause chronic inflammation [1]. Chronic infection
results in a decline of respiratory function and eventual
pulmonary failure, despite aggressive and repeated use of
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antibiotics. Although the overall process of disease progression is unfortunately predictable, individual rates of
progression can vary tremendously, leaving some CF patients relatively healthy in their 30s and others in need
of lung transplants in their teens [2].
Pseudomonas aeruginosa is an opportunistic pathogen
found in approximately 80% of adult CF patients. It is the
presumed cause of most pulmonary exacerbations and
therefore the major target of antibiotic treatment in CF
patients [3]. Culture-dependent techniques applied to
the study of CF sputum are used to identify antibioticresistant and susceptible strains of P. aeruginosa, as well
as Haemophilus influenzae, Burkholderia cepacia complex,
Staphylococcus aureus, Stenotrophomonas maltophilia and
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methicillin-resistant S. aureus, which also contribute to
the etiology of the CF phenotype [4]. Culture-independent
techniques (for example, 454 pyrosequencing of the bacterial 16S rRNA gene) can identify over 100 distinct genera, including the commensal genera that provide the
microbial diversity found in children that gradually disappears in adults. The results of studies such as those published by Cox et al. [5] and Madan et al. [6] show that the
diversity of the CF microbiome peaks during childhood,
then falls during the second decade of life, when it is more
frequently dominated by P. aeruginosa. Goddard et al. [7]
showed that end-stage CF is associated with reduced
community diversity and domination by a few antibioticresistant pathogens such as P. aeruginosa and B. cepacia
complex.
Investigators in a recent study of CF twins found that
pulmonary function among monozygous (MZ) twins is
more similar than that between dizygous (DZ) twin and
sibling pairs, regardless of whether they live together or
apart [8], suggesting that genetic modifiers play significant
roles in CF pulmonary function. In their study, genetic
factors accounted for 50% of pulmonary function variation, and, collectively, the remaining 50% were explained
by both stochastic and deterministic environmental influences. Specifically, unique environmental or stochastic
factors accounted for 36%, and shared environmental factors accounted for 14% of the remaining variation. Infection with environmental pathogens such as P. aeruginosa
contributes substantially to the progression of lung disease
in CF [9-11]; thus it is reasonable to expect that genetic
and/or nongenetic modifiers also impact infections. Indeed, the timing of development of chronic P. aeruginosa
infection was more similar in MZ twins than in DZ twins
or other siblings, suggesting a strong genetic influence
of this trait [12].
In this study, we hypothesized that environmental factors substantially influence the development of the CF
pediatric microbiome, suggesting the possibility of manipulating these communities to a more healthful state.
We provide new insight into the mechanisms by which
shared environment contributes to infection status in CF
patients.

Methods
Patient consent and ethical approval

Adults who were 18 years of age or older with CF confirmed by genotype analysis were recruited from the
CF program at Dartmouth-Hitchcock Medical Center
(DHMC). They provided written informed consent as
approved by the DHMC Institutional Review Board.
Children ages 10 to 18 years old with CF confirmed by
genotype analysis were recruited from the CF program
at Johns Hopkins University School of Medicine. They
provided written informed consent as approved by the
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Johns Hopkins University School Institutional Review
Board.
Data collection and statistical analysis

We analyzed the microbiome in the sputum from thirteen
clinically stable pediatric siblings from six families, of
which eight siblings were MZ twins and five were siblings
who served as proxies for DZ twins because they differed
in age by less than 3 years from the other child with CF
living in the same household. We compared the sputum
microbiomes of these pediatric patients (median age:
14 years) with each other and also to those of ten clinically
stable adults with CF chosen as randomly assigned controls in an adult CF microbiome study (median age:
30 years) living apart [13]. The detailed demographics of
these samples can be found in Additional file 1: Tables S1
and S2. Pediatric samples were collected in accordance
with induced sputum protocols [14], and adult samples
were spontaneously produced as described by Gifford
et al. [13]. As CF twins are rare, our CF pediatric samples
were collected at seven different regional CF centers from
Texas to New York. Adult samples were collected at
DHMC. DNA isolated from the resulting 43 samples was
deep-sequenced, and unique genera were identified on the
basis of variable regions of the bacterial 16S ribosomal
gene as previously reported [15]. Three replicate samples
from adults were averaged to form ten representative samples. The sequence reads were similar between sets, with
an average of approximately 15,000 reads per pediatric
sample and about 12,000 reads per adult sample.
Bray-Curtis dissimilarity and Shannon Diversity Index
were measured using the ecodist [16] and vegan [17]
packages in R statistical software. Significant differences
between groups were established using analysis of variance with Tukey’s Honest Significant Difference posttest.
Tests producing a P value less than 0.05 were deemed
significant. The pediatric data sets have been deposited
in the Sequence Read Archive database (NCBI BioProject
PRJNA237382; National Center for Biotechnology Information (NCBI), US National Library of Medicine,
Bethesda, MD, USA), and all data sets are also available
at http://vamps.mbl.edu/ (Visualization and Analysis of
Microbial Population Structures (VAMPS), Josephine Bay
Paul Center, Woods Hole, MA, USA) [18]. A summary of
the sequencing data read numbers and fractions can be
found in the supplemental data (Additional file 2).

Results
Figure 1A shows the fraction of reads and associated
bacterial genera for each of our 13 pediatric patients
from 6 different families. Notably, the microbiomes of
these pediatric patients is dominated by Streptococcus
spp., and P. aeruginosa accounted for a small fraction of
reads in any given sample. Comparing siblings living
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Figure 1 Analysis of microbial communities in pediatric and adult patients. (A) Nineteen genera accounted for 85% of the reads in sputum
collected from thirteen pediatric patients with cystic fibrosis (CF). Data are presented in a stacked bar chart of relative abundance as fractions of
total reads (y-axis) for the top 19 genera for each patient (x-axis). Families are numbered 1 to 6, and pairs of monozygous twins are connected
with a red dash. The color key indicating these 19 genera is shown at the bottom of the figure. Pediatric samples contain a large fraction of
genus Streptococcus, shown at the bottom of the bars in maroon. (B) Fifteen genera accounted for 85% of the reads in sputum collected from
ten adult patients with CF. Adult samples are often dominated by the genus Pseudomonas, shown in black. Burkholderia, shown in green, is
dominant in patient 8.

together to unrelated individuals reveals that the environment plays an important role in determining the composition of the microbiota. Both identical twins and siblings
living together (twins connected by a red dash in Figure 1A)
have very similar communities. For example, siblings in
families 1 and 6 are much more like each other than they
are to children from other families (Figure 1A). We also
compared the microbiomes of pediatric CF patients using
Bray-Curtis dissimilarity analysis (Figure 2A), which
confirmed that the siblings from the same family are
significantly more similar to each other than they are to
unrelated pediatric CF patients. Importantly, there was
no significant difference in relatedness of communities
between MZ twins versus nontwin siblings with CF
(a proxy for DZ twins) living together, despite the genetic

differences in these cohorts. This finding supports the hypothesis that the environment may influence the airway
community.
Figure 1B shows the fraction of reads and associated
bacterial genera for ten unrelated adult patients. In contrast to the pediatric CF patient cohort, the microbiomes
of adult CF patients are dominated by P. aeruginosa,
with relatively little Streptococcus. In addition, a visual
inspection of the communities in the pediatric and adult
CF cohorts indicated that microbiome diversity is higher
in the pediatric cohort than in the adult cohort (compare Figure 1A with Figure 1B). This observation was
confirmed by analysis of diversity using the Shannon
Diversity Index (Figure 2B) and is consistent with previous work showing that the biomes of infants with CF are
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Figure 2 Relatedness and diversity of microbial communities. (A) Box-and-whisper plots of pairwise Bray-Curtis distances of the microbiomes
of pediatric cystic fibrosis (CF) patients as a function of genetic relatedness, showing significantly more distance between unrelated patients than
between related patients (P = 0.01), but no significant difference in relatedness between monozygotic (MZ) twins and nontwin siblings with CF
(a proxy for dizygotic (DZ) twins, labeled “DZ Sibling”). Boxes indicate median values as the center line of each box, which spans the interquartile
range. Whiskers demarcate 1.5× the interquartile range. These values reflect 70 pairwise comparisons among the samples from the ten unrelated
subjects, and four pairwise comparisons among samples from the five siblings. (B) Boxplots comparing Shannon Diversity Index in all children
with CF in this study and adults with CF reveal significantly lower diversity in adult versus the pediatric cohort (P = 0.001). Median Shannon Diversity
Index value from adult patients in the Tunney et al. study [19] is shown as the red line, and the median Shannon Diversity Index score in adult patients
reported by Zhao et al. [20] is shown as a blue line for comparison to our adult cohort. Whiskers denote 1.5 times the interquartile range defined by
the box. Open circles denote outlier values outside this range. Significance codes: ‘***’ P < 0.001; ‘**’ P < 0.01.

dominated by Veillonella and Streptococcus. Diversity
rapidly increases in the first 21 months of life [6] and
peaks at around 11 years of age [21].

Conclusions
Our analysis of the sputum microbiomes in pediatric
CF patients supports the conclusion that environmental
factors—that is, all manner of nongenetic factors—play
an important role in determining the composition of the
CF microbiome and is in agreement with the results of
other studies of adults with CF that the environment is
an important determinant of the microbiomes found in
these patients [22]. We found that the microbiomes of
pediatric CF patients living together are much more
alike than those among individuals living apart, and, importantly, there was no significant difference between affected MZ twins and affected siblings living together.
These observations are consistent with the view that the
environment is an important factor in determining the
composition of the microbiome. Although it is possible
that a much larger sample size might resolve subtle differences between affected siblings living together and
affected MZ twins living together, we saw no such difference in our small study. Nonetheless, we could easily see
differences between pediatric patients living in the same
house compared to those living apart. In any case, numerous studies have identified an inverse relationship
between microbial diversity and lung function, as well
as inflammatory markers, in airway samples of adults
[23,24]. These observations suggest that novel therapeutic regimens that maintain diversity while reducing
total bacterial load may improve clinical outcomes and

prevent the development of a microbiome dominated by
mucoid P. aeruginosa that is tolerant to antibiotic therapy. It is also possible that early exposure to microbes
and allergens permanently shapes the developing microbial community in the lungs of CF patients. Such imprinting could mean that patients who live together are
exposed to, and therefore colonized by, the same microbes. It would be interesting to know whether the
microbiota of these pediatric CF patients living together
would begin to diverge when they are removed from the
same home environment.
Importantly, the observation described herein that the
pediatric microbiome can be influenced by environment
suggests that the microbial communities in these patients
might be amenable to manipulation. We hypothesize that
early intervention to enhance or maintain the diversity of
the microbiota of young CF patients, perhaps by using
probiotics, holds promise for slowing disease progression
until a cure is found for this pernicious disease. Although
our data suggest that maintaining pediatric microbial diversity into adulthood may lead to better outcomes, effective strategies to maintain diversity will require a clearer
understanding of how microbial communities in the CF
pediatric airway evolve under the selective pressure of repeated antibiotic treatment.

Availability of supporting data
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Additional files
Additional file 1: Table S1 and Table S2. Two supplemental tables
summarizing the patient data for the patient cohorts that were the
subject of the study. CF, Cystic fibrosis; MaxFEV1, Maximum volume
exhaled at end of first second of forced expiration.
Additional file 2: Sequence data. Summary of demographic data of
each sample analyzed, as well the number and fraction of reads from
adult and pediatric samples.
Abbreviations
CF: Cystic fibrosis; DZ: Dizygous; MZ: Monozygous.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
THH performed statistical analyses and manuscript writing. DMG, HGM and
AHG performed data collection and analysis and manuscript writing. GRC,
BAS and GAO were responsible for the conception and design of the study
and securing financial support, and participated in writing the manuscript.
MLS performed data collection and analysis and secured financial support,
and participated in writing the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported by the Flatley Foundation of Boston (to GAO, BAS
and AHG), National Institutes of Health (NIH) grants P20 GM103413-10 and
R01 HL074175-09 (to BAS), a Cystic Fibrosis Foundation Research Development
Program grant (STANTO07R0), Cystic Fibrosis Foundation Research Development
Program grant R025-CR07 (to DMG), NIH grants R01 HL068927-09 and R01
DK44003 (to GRC), Cystic Fibrosis Foundation grant CUTTIN06P0 (to GRC),
NIH grant R01 AI091699 (to GAO) and NIH grant 4UH3DK083993 (to MLS).
Author details
1
Department of Microbiology and Immunology, Geisel School of Medicine at
Dartmouth, 615 Remsen Building, N. College St., Hanover, NH 03755, USA.
2
Division of Pediatric Pulmonary and Sleep Medicine, Duke University
Medical Center, 350 Hanes House, DUMC Box 102360, Durham, NC, USA.
3
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University
School of Medicine, 1800 Orleans St., Baltimore, MD, USA. 4Josephine Bay
Paul Center for Comparative Molecular Biology and Evolution, Marine
Biological Laboratory, 7 MBL Street, Woods Hole, MA 02543, USA.
5
Department of Microbiology and Immunology, Geisel School of Medicine at
Dartmouth, 202 Remsen Building, N. College St., Hanover, NH 03755, USA.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.
17.
18.

19.

20.

Received: 1 February 2014 Accepted: 27 March 2014
Published: 28 April 2014
References
1. Chmiel JF, Davis PB: State of the art: Why do the lungs of patients with
cystic fibrosis become infected and why can’t they clear the infection?
Respir Res 2003, 4:8.
2. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, Marinelli I,
Messore B, Neri AS, Raia V, Mastella G: An overview of international
literature from cystic fibrosis registries. Part 4: Update 2011. J Cyst Fibros
2012, 11:480–493.
3. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR: Results of antibiotic
susceptibility testing do not influence clinical outcome in children with
cystic fibrosis. J Cyst Fibros 2012, 11:288–292.
4. Lynch SV, Bruce KD: The cystic fibrosis airway microbiome. Cold Spring
Harb Perspect Med 2013, 3:a009738.
5. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U,
Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME,
Nielson D, Brodie EL, Lynch SV: Airway microbiota and pathogen
abundance in age-stratified cystic fibrosis patients. PLoS One 2010,
5:e11044.
6. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML,
Moore JH, Guill MF, Morrison HG, Sogin ML, Hampton TH, Karagas MR,
Palumbo PE, Foster JA, Hibberd PL, O’Toole GA: Serial analysis of the gut

21.

22.

23.

24.

and respiratory microbiome in cystic fibrosis in infancy: interaction
between intestinal and respiratory tracts and impact of nutritional
exposures. MBio 2012, 3:e00251–12.
Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML,
Fligner CL, Singh PK: Direct sampling of cystic fibrosis lungs indicates that
DNA-based analyses of upper-airway specimens can misrepresent lung
microbiota. Proc Natl Acad Sci U S A 2012, 109:13769–13774.
Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR:
Quantification of the relative contribution of environmental and genetic
factors to variation in cystic fibrosis lung function. J Pediatr 2010,
157:802–807. e1–e3.
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL: Pseudomonas
aeruginosa and other predictors of mortality and morbidity in young
children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91–100.
Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF,
Grimwood K: Clinical outcome after early Pseudomonas aeruginosa
infection in cystic fibrosis. J Pediatr 2001, 138:699–704.
Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG,
Collins J, Farrell PM: Acceleration of lung disease in children with cystic
fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001,
32:277–287.
Green DM, Collaco JM, McDougal KE, Naughton KM, Blackman SM, Cutting GR:
Heritability of respiratory infection with Pseudomonas aeruginosa in cystic
fibrosis. J Pediatr 2012, 161:290–295. e1.
Gifford AH, Alexandru DM, Li Z, Dorman DB, Moulton LA, Price KE, Hampton TH,
Sogin ML, Zuckerman JB, Parker HW, Stanton BA, O’Toole GA: Iron
supplementation does not worsen respiratory health or alter the sputum
microbiome in cystic fibrosis. J Cyst Fibros 2014, 13:311–318.
Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML: Sputum induction as a
research tool for sampling the airways of subjects with cystic fibrosis.
Thorax 2001, 56:306–311.
Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG,
Sogin ML, O’Toole GA: Unique microbial communities persist in individual
cystic fibrosis patients throughout a clinical exacerbation. Microbiome
2013, 1:27.
Goslee SC, Urban DL: The ecodist package for dissimilarity-based analysis
of ecological data. J Stat Softw 2007, 22(7):1–19.
Dixon P: VEGAN, a package of R functions for community ecology. J Veg
Sci 2003, 14:927–930.
Huse SM, Welch DBM, Voorhis A, Shipunova A, Morrison HG, Eren AM, Sogin ML:
VAMPS: a website for visualization and analysis of microbial population
structures. BMC Bioinformatics 2014, 15:41.
Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M,
Boucher RC, Wolfgang MC, Elborn JS: Lung microbiota and bacterial
abundance in patients with bronchiectasis when clinically stable and
during exacerbation. Am J Respir Crit Care Med 2013, 187:1118–1126.
Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF,
Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ:
Decade-long bacterial community dynamics in cystic fibrosis airways.
Proc Natl Acad Sci U S A 2012, 109:5809–5814.
Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA,
Lory S, Brodie EL, Lynch SV, Bohannan BJ, Green JL, Maurer BA, Kolter R:
Relationship between cystic fibrosis respiratory tract bacterial
communities and age, genotype, antibiotics and Pseudomonas
aeruginosa. Environ Microbiol 2010, 12:1293–1303.
Psoter KJ, De Roos AJ, Wakefield J, Mayer J, Rosenfeld M: Season is
associated with Pseudomonas aeruginosa acquisition in young children
with cystic fibrosis. Clin Microbiol Infect 2013, 19:E483–E489.
Blainey PC, Milla CE, Cornfield DN, Quake SR: Quantitative analysis of the
human airway microbial ecology reveals a pervasive signature for cystic
fibrosis. Sci Transl Med 2012, 4:153ra130.
Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP,
Hoffman L, Daniels TW, Patel N, Forbes B, Bruce KD: Long-term
cultivation-independent microbial diversity analysis demonstrates that
bacterial communities infecting the adult cystic fibrosis lung show stability
and resilience. Thorax 2012, 67:867–873.

doi:10.1186/2049-2618-2-14
Cite this article as: Hampton et al.: The microbiome in pediatric cystic
fibrosis patients: the role of shared environment suggests a window of
intervention. Microbiome 2014 2:14.

